For this reason, treatment of anti-IL-17 monoclonal antibody has been applied in mice with myocarditis and gained a desirable efficacy of abrogating cardiac fibrosis and slowing down the aggravation of ventricular function (30). This evidence concerns the gene IL17A and fibrosis.